Healthcare Industry News: Eli Lilly
News Release - June 21, 2012
Clarus Therapeutics Appoints Bela S. Denes, M.D. as Chief Medical OfficerNORTHBROOK, Ill, June 21, 2012 -- (Healthcare Sales & Marketing Network) -- Clarus Therapeutics, Inc. today announced the appointment of Bela S. Denes, M.D. to the newly created role of chief medical officer. Dr. Denes was most recently senior medical director at Abbott Laboratories where he was responsible for development of therapeutics in the company's Men's Health Division.
Robert E. Dudley, Ph.D., chief executive officer of Clarus Therapeutics commented, "Bela's extensive clinical and industry experience in urology and men's health will be invaluable as CLR-610, our oral testosterone replacement candidate, nears the end of Phase 3 clinical development. We welcome Bela to our team, and look forward to working with him during this transformative time at Clarus."
Bela S. Denes, M.D. has over 35 years of urology experience as a laboratory researcher, clinical investigator, pharmaceutical program director and practicing physician. Dr. Denes most recently served as senior medical director at Abbott Laboratories where he led therapeutic drug discovery and development efforts in their Men's Health Division. Previous to Abbott, Dr. Denes served as the senior director of medical affairs at Pfizer. He also spent four years with Eli Lilly where he was involved with the clinical development and launch of Cialis(R) (tadalafil) for ED and BPH. Prior to his tenure at Lilly, Dr. Denes spent 23 years in academic and clinical practice. He is certified by the American Board of Urology and is a member of the American College of Surgeons. Dr. Denes completed his medical school and residency training at Washington University in St. Louis, MO.
"Given the concerns with currently available testosterone replacement therapies, I believe that a safe and effective oral formulation could have enormous market potential," added Dr. Denes. "The recent conclusion of patient enrollment in the Phase 3 study and anticipation of top-line data later this year, makes this an exciting time to join Clarus."
About Clarus Therapeutics
Clarus is a privately held biopharmaceutical company focused on the development and commercialization of our oral T replacement product, CLR-610, currently in Phase 3 clinical testing. According to the American Urological Association, 10% of men 40-to-60 years of age, and 20% over the age of 60 have low T levels. Common symptoms associated with low T may include mild depression, reduced sex drive and erectile function, increased body fat, and decreased energy, lean body mass, muscle strength and bone mineral density. For more information, please visit: www.clarustherapeutics.com.
Source: Clarus Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.